NCT03306381

Brief Summary

The aim of the present study is to research whether subjects with irritable bowel syndrome (IBS) display epigenetic/genetic changes or altered microbiota compared to a non-IBS control group. Further, we will investigate if these parameters as well as subjective IBS symptoms are affected by a 4-week long dietary intervention within the IBS patient group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
105

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2017

Completed
23 days until next milestone

First Posted

Study publicly available on registry

October 11, 2017

Completed
3 months until next milestone

Study Start

First participant enrolled

January 15, 2018

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2019

Completed
Last Updated

December 10, 2019

Status Verified

December 1, 2019

Enrollment Period

1.1 years

First QC Date

September 18, 2017

Last Update Submit

December 9, 2019

Conditions

Keywords

IBSEpigeneticsDietary interventionGut MicrobiotaInflammationGenetics

Outcome Measures

Primary Outcomes (1)

  • Genetic variation of enzymes regulating absorption of disaccharides

    Genetic expression of disaccharide-degradating enzymes will be measured at baseline and related to the response of study participants to dietary intervention.

    measured at baseline

Secondary Outcomes (5)

  • Irritable bowel syndrome-subjective severity scores (IBS-SSS) ratings

    4 weeks

  • Visual analog scale for irritable bowel syndrome (VAS-IBS) ratings

    4 weeks

  • Gut microbiota composition

    4 weeks

  • Cytokines

    4 weeks

  • microRNA expression

    4 weeks

Study Arms (2)

Dietary intervention subject group

EXPERIMENTAL

n=130. Participants on low FODMAP-similar diet during 4-week study period.

Other: Dietary intervention

Control group

NO INTERVENTION

n=20. Participants on traditional IBS diet during 4-week study period.

Interventions

Elimination of certain products.

Dietary intervention subject group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Verified IBS according to Rom IV criteria.

You may not qualify if:

  • Serious mental or somatic disease
  • Abuse
  • Inability to understand he Swedish language
  • Already on a diet (e.g. vegan, FODMAP, gluten-free).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Deartment of INternal Medicine

Malmo, 20502, Sweden

Location

Related Publications (2)

  • Roth B, Ohlsson B. Overweight and vitamin D deficiency are common in patients with irritable bowel syndrome - a cross-sectional study. BMC Gastroenterol. 2024 Sep 3;24(1):296. doi: 10.1186/s12876-024-03373-x.

  • Nilholm C, Manoharan L, Roth B, D'Amato M, Ohlsson B. A starch- and sucrose-reduced dietary intervention in irritable bowel syndrome patients produced a shift in gut microbiota composition along with changes in phylum, genus, and amplicon sequence variant abundances, without affecting the micro-RNA levels. United European Gastroenterol J. 2022 May;10(4):363-375. doi: 10.1002/ueg2.12227. Epub 2022 Apr 28.

MeSH Terms

Conditions

Irritable Bowel SyndromeInflammation

Interventions

Diet Therapy

Condition Hierarchy (Ancestors)

Colonic Diseases, FunctionalColonic DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Nutrition TherapyTherapeutics

Study Officials

  • Bodil Ohlsson, MD, PhD

    Region Skane

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2017

First Posted

October 11, 2017

Study Start

January 15, 2018

Primary Completion

February 28, 2019

Study Completion

February 28, 2019

Last Updated

December 10, 2019

Record last verified: 2019-12

Data Sharing

IPD Sharing
Will not share

Locations